Ola Lindén

1.4k total citations
36 papers, 1.0k citations indexed

About

Ola Lindén is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Ola Lindén has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 19 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Oncology. Recurrent topics in Ola Lindén's work include Lymphoma Diagnosis and Treatment (23 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Ola Lindén is often cited by papers focused on Lymphoma Diagnosis and Treatment (23 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Ola Lindén collaborates with scholars based in Sweden, Germany and United Kingdom. Ola Lindén's co-authors include Cécilia Hindorf, Glenn Flux, Gerhard Glatting, Claudio Chiesa, Jan Tennvall, Sven‐Erik Strand, Lars Stenberg, Elisabeth Kjellén, Walter Noordzij and Jae H. Park and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ola Lindén

36 papers receiving 1.0k citations

Peers

Ola Lindén

RNMI

PRM

ONCOL

PFM

RADIA

Christian Baues Germany

Dominick Lamonica United States

Alexander Matthies Germany

Chul Yong Kim South Korea

Denise Regan United States

Carol Marquez United States

Lawrence D. Durack United States

Mario Roncadin Italy

Dave Yamauchi United States

Gabriele Reinartz Germany

Christian Baues Germany

Ola Lindén

333 ×0.5

RNMI

393 ×1.2

PRM

466 ×1.4

ONCOL

416 ×1.4

PFM

128 ×0.8

RADIA

Citations per year, relative to Ola Lindén Ola Lindén (= 1×) peers Christian Baues

Countries citing papers authored by Ola Lindén

Since Specialization

Citations

This map shows the geographic impact of Ola Lindén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Lindén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Lindén more than expected).

Fields of papers citing papers by Ola Lindén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ola Lindén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Lindén. The network helps show where Ola Lindén may publish in the future.

Co-authorship network of co-authors of Ola Lindén

This figure shows the co-authorship network connecting the top 25 collaborators of Ola Lindén. A scholar is included among the top collaborators of Ola Lindén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola Lindén. Ola Lindén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sonnevi, Kristina, et al.. (2023). Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly. SHILAP Revista de lepidopterología. 4(3). 647–655. 2 indexed citations

Rieger, Kathrin, Rosaria De Filippi, Ola Lindén, et al.. (2022). 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. Annals of Hematology. 101(4). 781–788. 11 indexed citations

Lindén, Ola, Andrew Bates, David Cunningham, et al.. (2021). ²²⁷ Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 36(8). 672–681. 22 indexed citations

Cleton, Adriaan, et al.. (2020). Feasibility of Thorium-227/Radium-223 Gamma-Camera Imaging During Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals. 35(7). 540–548. 13 indexed citations

Lindén, Ola, et al.. (2015). Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib. PubMed. 15(1). 10–10. 18 indexed citations

Kimby, Eva, Bjørn Østenstad, Peter de Nully Brown, et al.. (2015). Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leukemia & lymphoma. 56(9). 2598–2607. 17 indexed citations

Wahlin, Björn E., Christer Sundström, Harald Holte, et al.. (2011). T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab. Clinical Cancer Research. 17(12). 4136–4144. 41 indexed citations

Lindén, Ola, et al.. (2011). Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. Experimental Cell Research. 317(8). 1179–1191. 12 indexed citations

Hindorf, Cécilia, Gerhard Glatting, Claudio Chiesa, Ola Lindén, & Glenn Flux. (2010). EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. European Journal of Nuclear Medicine and Molecular Imaging. 37(6). 1238–1250. 217 indexed citations

10.

Minarik, David, Katarina Sjögreen Gleisner, Ola Lindén, et al.. (2010). ⁹⁰Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy. Journal of Nuclear Medicine. 51(12). 1974–1978. 44 indexed citations

11.

Strand, Sven‐Erik, et al.. (2009). Development and Evaluation of a Pharmacokinetic Model for Prediction of Radioimmunotherapy Based on Pretherapy Data. Cancer Biotherapy and Radiopharmaceuticals. 24(1). 111–122. 6 indexed citations

12.

Lindén, Ola, Lars Stenberg, & Elisabeth Kjellén. (2008). Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncologica. 48(1). 158–159. 55 indexed citations

13.

Hindorf, Cécilia, Dimitris Emfietzoglou, Ola Lindén, et al.. (2007). Single-Cell Dosimetry for Radioimmunotherapy of B-Cell Lymphoma Patients with Special Reference to Leukemic Spread. Cancer Biotherapy and Radiopharmaceuticals. 22(3). 357–366. 17 indexed citations

14.

Brans, Boudewijn, Ola Lindén, Francesco Giammarile, Jan Tennvall, & Cornelis J. A. Punt. (2006). Clinical applications of newer radionuclide therapies. European Journal of Cancer. 42(8). 994–1003. 41 indexed citations

15.

Brown, Peter de Nully, Jesper Jurlander, Ola Lindén, & Mads Hansen. (2005). Radioimmunoterapi ved non-Hodgkins lymfom. Ugeskrift for Læger. 167(41). 9–3867. 1 indexed citations

16.

Hindorf, Cécilia, Ola Lindén, Jan Tennvall, Karin Wingårdh, & Sven‐Erik Strand. (2005). Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy. Acta Oncologica. 44(6). 579–588. 14 indexed citations

17.

Lindén, Ola, Jan Kurkus, Michael Garkavij, et al.. (2005). A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and ⁹⁰ Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 457–466. 28 indexed citations

18.

Hindorf, Cécilia, Dimitris Emfietzoglou, Ola Lindén, Kostas Kostarelos, & Sven‐Erik Strand. (2005). Internal Microdosimetry for Single Cells in Radioimmunotherapy of B-Cell Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 20(2). 224–230. 19 indexed citations

19.

Lindén, Ola, Jan Tennvall, Cécilia Hindorf, et al.. (2002). 131 I-labelled Anti-CD22 MAb (LL2) in Patients with B-Cell Lymphomas Failing Chemotherapy. Acta Oncologica. 41(3). 297–303. 9 indexed citations

20.

Lindén, Ola, Eva Cavallin‐Ståhl, Tomas Ohlsson, et al.. (2001). Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule. Lund University Publications (Lund University). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact